Teleflex Inc
TFX
ISIN null / Valor 976212
Teleflex Inc
UMushroom community rating:
About company
Teleflex Inc is a global company specializing in medical technologies aimed at enhancing the health and well-being of individuals. With a diverse portfolio of solutions in areas such as vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine, and respiratory care, Teleflex focuses on purpose-driven innovation to address unmet clinical needs and improve patient outcomes. With over 14,000 employees worldwide, the company is committed to making a difference in the healthcare industry through its innovative products and services.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (15.11.2025):
Teleflex Inc reported its financial results for the second quarter of 2025 with improved performance across key metrics. The company achieved GAAP revenue of $780.9 million – a 4.2% increase over the prior year – and significantly boosted its GAAP diluted earnings per share from continuing operations to $2.77 (up from $1.69). Adjusted diluted EPS also rose to $3.73 compared to $3.42 last year, while full-year guidance has been raised following the recent acquisition of BIOTRONIK’s Vascular Intervention business.
Revenue Growth
GAAP revenue reached $780.9 million, reflecting a 4.2% year-over-year increase, with adjusted constant currency revenue growing by 1.0%, highlighting solid market demand in the quarter.
Earnings Improvement
Teleflex Inc’s earnings showed notable improvement, with GAAP diluted EPS rising from $1.69 to $2.77 and adjusted diluted EPS increasing from $3.42 to $3.73, underscoring efficient cost management and strong operational performance.
Guidance Upgrades
The company raised its full-year 2025 outlook, increasing its GAAP revenue growth guidance to a range of 9.00% to 10.00% and adjusting EPS guidance upward, driven largely by the strategic acquisition of BIOTRONIK’s Vascular Intervention business.
Segment and Product Performance
Across regions, the Americas and EMEA segments contributed to the growth, with the EMEA region reporting a notable increase in the three-month period. Additionally, product category performance, particularly in interventional products, showed robust growth, reinforcing Teleflex Inc's diversified portfolio and positioning in key therapeutic areas.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
4872 M
Market cap (USD)
491,075
Daily traded volume (Shares)
178.18 / 175.46
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
